Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acetyl-L-carnitine in Alzheimer's Disease
NCT02955706Phase 4Completed
- Sponsor
- Dong-A ST
- Start
- Apr 2016
- Primary completion
- Sep 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in Alzheimer's disease (AD) comparing Acetyl-L-carnitine with Placebo (2 arms). Primary endpoint: Alzheimer's Disease Assessment Scale-cognitive subscale at 24 weeks. Started Apr 2016; status: completed.
02
Drugs
acetyl-l-carnitine
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT02955706.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02955706.